Royalty Pharma Statistics
Total Valuation
Royalty Pharma has a market cap or net worth of $31.65 billion. The enterprise value is $40.19 billion.
Important Dates
The last earnings date was Wednesday, May 6, 2026, before market open.
| Earnings Date | May 6, 2026 |
| Ex-Dividend Date | May 15, 2026 |
Share Statistics
Royalty Pharma has 575.83 million shares outstanding. The number of shares has decreased by -5.11% in one year.
| Current Share Class | 443.27M |
| Shares Outstanding | 575.83M |
| Shares Change (YoY) | -5.11% |
| Shares Change (QoQ) | +0.15% |
| Owned by Insiders (%) | 6.86% |
| Owned by Institutions (%) | 82.89% |
| Float | 410.36M |
Valuation Ratios
The trailing PE ratio is 28.87 and the forward PE ratio is 10.53. Royalty Pharma's PEG ratio is 0.96.
| PE Ratio | 28.87 |
| Forward PE | 10.53 |
| PS Ratio | 13.04 |
| Forward PS | 8.96 |
| PB Ratio | 3.48 |
| P/TBV Ratio | 5.34 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 12.18 |
| PEG Ratio | 0.96 |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | 48.64 |
| EV / Sales | 16.47 |
| EV / EBITDA | n/a |
| EV / EBIT | 24.24 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.66, with a Debt / Equity ratio of 0.90.
| Current Ratio | 2.66 |
| Quick Ratio | 2.64 |
| Debt / Equity | 0.90 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | 4.93 |
Financial Efficiency
Return on equity (ROE) is 13.77% and return on invested capital (ROIC) is 5.71%.
| Return on Equity (ROE) | 13.77% |
| Return on Assets (ROA) | 5.54% |
| Return on Invested Capital (ROIC) | 5.71% |
| Return on Capital Employed (ROCE) | 8.60% |
| Weighted Average Cost of Capital (WACC) | 5.66% |
| Revenue Per Employee | $24.41M |
| Profits Per Employee | $8.26M |
| Employee Count | 100 |
| Asset Turnover | 0.13 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +65.27% in the last 52 weeks. The beta is 0.40, so Royalty Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.40 |
| 52-Week Price Change | +65.27% |
| 50-Day Moving Average | 50.38 |
| 200-Day Moving Average | 42.33 |
| Relative Strength Index (RSI) | 64.46 |
| Average Volume (20 Days) | 4,333,453 |
Short Selling Information
The latest short interest is 12.68 million, so 2.20% of the outstanding shares have been sold short.
| Short Interest | 12.68M |
| Short Previous Month | 13.82M |
| Short % of Shares Out | 2.20% |
| Short % of Float | 3.09% |
| Short Ratio (days to cover) | 3.68 |
Income Statement
In the last 12 months, Royalty Pharma had revenue of $2.44 billion and earned $826.29 million in profits. Earnings per share was $1.90.
| Revenue | 2.44B |
| Gross Profit | 2.81B |
| Operating Income | 1.66B |
| Pretax Income | 1.36B |
| Net Income | 826.29M |
| EBITDA | n/a |
| EBIT | 1.66B |
| Earnings Per Share (EPS) | $1.90 |
Full Income StatementBalance Sheet
The company has $608.30 million in cash and $8.97 billion in debt, with a net cash position of -$8.37 billion or -$14.53 per share.
| Cash & Cash Equivalents | 608.30M |
| Total Debt | 8.97B |
| Net Cash | -8.37B |
| Net Cash Per Share | -$14.53 |
| Equity (Book Value) | 9.94B |
| Book Value Per Share | 15.53 |
| Working Capital | 890.13M |
Full Balance SheetCash Flow
| Operating Cash Flow | 2.61B |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 5.02M |
| Net Borrowing | 954.48M |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Full Cash Flow StatementMargins
Gross margin is 115.00%, with operating and profit margins of 67.93% and 33.86%.
| Gross Margin | 115.00% |
| Operating Margin | 67.93% |
| Pretax Margin | 55.64% |
| Profit Margin | 33.86% |
| EBITDA Margin | n/a |
| EBIT Margin | 67.93% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of $0.94, which amounts to a dividend yield of 1.71%.
| Dividend Per Share | $0.94 |
| Dividend Yield | 1.71% |
| Dividend Growth (YoY) | 5.81% |
| Years of Dividend Growth | 6 |
| Payout Ratio | 47.79% |
| Buyback Yield | 5.11% |
| Shareholder Yield | 6.81% |
| Earnings Yield | 2.60% |
| FCF Yield | n/a |
Dividend DetailsAnalyst Forecast
The average price target for Royalty Pharma is $59.25, which is 7.79% higher than the current price. The consensus rating is "Buy".
| Price Target | $59.25 |
| Price Target Difference | 7.79% |
| Analyst Consensus | Buy |
| Analyst Count | 10 |
| Revenue Growth Forecast (3Y) | 18.45% |
| EPS Growth Forecast (3Y) | 27.13% |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Royalty Pharma has an Altman Z-Score of 1.61 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.61 |
| Piotroski F-Score | 6 |
